Pegaspargase

Pegaspargase
Clinical data
Pronunciation	/pəˈɡæspərɡeɪz/
Trade names	Oncaspar
AHFS/Drugs.com	Monograph
MedlinePlus	a695031
License data	EU EMA: by INN; US DailyMed: Pegaspargase;
Pregnancy; category	AU: D; ;
Routes of; administration	Intramuscular, intravenous
ATC code	L01XX24 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only) ; US: ℞-only ; EU: Rx-only ;
Identifiers
	IUPAC name Pegylated E. coli L-asparagine amidohydrolase;
CAS Number	130167-69-0 ;
DrugBank	DB00059 ;
ChemSpider	none;
UNII	7D96IR0PPM;
KEGG	D05387;
ChEMBL	ChEMBL2108546;
Chemical and physical data
Formula	C1377H2208N382O442S17
Molar mass	31732.06 g·mol−1
	(what is this?)

Pegaspargase, sold under the brand name Oncaspar, is a medication used in the treatment of acute lymphoblastic leukemia (ALL).^[2] Often it is used together with anthracycline, vincristine, and prednisone.^[3] It is used by injection.^[3]

Common side effects include allergic reactions, blood clotting problems, high blood sugar, liver problems, pancreas inflammation, and blood clots in the brain.^[3] Its use during pregnancy may harm the baby.^[4] It is a modified version of the enzyme asparaginase which has undergone PEGylation.^[5]^[3] It works by breaking down asparagine, decreasing its availability to make protein.^[3]

Pegaspargase was approved for medical use in the United States in 1994.^[3] It is on the World Health Organization's List of Essential Medicines.^[6] It is made by Sigma-Tau.^[3]

References[]

^ "Oncaspar EPAR". European Medicines Agency (EMA). Retrieved 21 January 2021.
^ Graham ML (2003). "Pegaspargase: a review of clinical studies". Adv. Drug Deliv. Rev. 55 (10): 1293–302. doi:10.1016/S0169-409X(03)00110-8. PMID 14499708.
^ ^a ^b ^c ^d ^e ^f ^g "Pegaspargase Monograph for Professionals". Drugs.com. Retrieved 11 October 2019.
^ "Pegaspargase (Oncaspar) Use During Pregnancy". Drugs.com. Retrieved 11 October 2019.
^ "UNM Cancer Center". Archived from the original on 3 September 2006. Retrieved 28 August 2007.
^ World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.

External links[]

"Pegaspargase". Drug Information Portal. U.S. National Library of Medicine.

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by .

[1] "Oncaspar EPAR". European Medicines Agency (EMA). Retrieved 21 January 2021.

[Gra2003-2] Graham ML (2003). "Pegaspargase: a review of clinical studies". Adv. Drug Deliv. Rev. 55 (10): 1293–302. doi:10.1016/S0169-409X(03)00110-8. PMID 14499708.

[AHFS2019-3] ^ ^a ^b ^c ^d ^e ^f ^g "Pegaspargase Monograph for Professionals". Drugs.com. Retrieved 11 October 2019.

[4] "Pegaspargase (Oncaspar) Use During Pregnancy". Drugs.com. Retrieved 11 October 2019.

[5] "UNM Cancer Center". Archived from the original on 3 September 2006. Retrieved 28 August 2007.

[WHO21st-6] World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.

[1]

[2]

[3]

[4]

[5]

[6]